Treatment

January 11, 2021

Learn About ILUMYA® (tildrakizumab-asmn) and Why Biologic Treatments May be Right for You

Watch this webinar to hear Dr. Neal Bhatia, Director and Clinical Dermatology Principal Investigator at Therapeutics Clinical Research, discuss moderate-to-severe plaque psoriasis, the benefits of biologic treatments, and provide an overview of ILUMYA® (tildrakizumab-asmn) as a treatment option. We also hear from Jim, one of Dr. Bhatia’s patients currently taking ILUMYA®, who shares his journey with moderate-to-severe plaque psoriasis and how he found a biologic treatment that works for him. Dr. Bhatia answers some frequently asked questions and shares some new research in the field of biologics.

ILUMYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills, or phototherapy. Healthcare providers should check the patient for infections and tuberculosis before starting treatment with ILUMYA®. Before starting any treatment, patients should talk to their doctor and review the important safety information to understand the potential risks. The most common (≥1%) adverse reactions associated with ILUMYA® are upper respiratory infections, injection site reactions, and diarrhea.

This webinar is sponsored by Sun Pharma. For Important Safety Information: https://bit.ly/2We7fIS.

Questions?

Contact Bev Bromfield, Outreach Manager, at bbromfield@psoriasis.org or 800-723-9166, ext. 362.

Sponsor

This webinar is sponsored by:

Sun Pharma Logo

National Psoriasis Foundation is solely responsible for all content and development.

Share
Related Items

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.